Lisata Therapeutics Executive Compensation Revealed
Ticker: LSTA · Form: DEF 14A · Filed: Apr 25, 2025 · CIK: 320017
| Field | Detail |
|---|---|
| Company | Lisata Therapeutics, Inc. (LSTA) |
| Form Type | DEF 14A |
| Filed Date | Apr 25, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, equity-awards, sec-filing, pharmaceuticals
TL;DR
Lisata's exec pay details out for 2024 - equity awards and adjustments are key.
AI Summary
Lisata Therapeutics, Inc. filed its DEF 14A on April 25, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted to its principal executive officers (PEO) and non-PEO NEO members, as well as adjustments to these awards. The company, formerly known as Caladrius Biosciences, Inc. and NeoStem, Inc., is in the pharmaceutical preparations industry.
Why It Matters
This filing provides transparency into how Lisata Therapeutics compensates its top executives, which can influence investor perception and the company's ability to attract and retain talent.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine disclosures, but the specifics of executive compensation can sometimes signal underlying company performance or strategic shifts.
Key Numbers
- 2024 — Fiscal Year (Reporting period for executive compensation details.)
- 2023 — Fiscal Year (Comparative compensation data may be available.)
- 2022 — Fiscal Year (Comparative compensation data may be available.)
Key Players & Entities
- Lisata Therapeutics, Inc. (company) — Filer
- Caladrius Biosciences, Inc. (company) — Former Company Name
- NeoStem, Inc. (company) — Former Company Name
- 20250425 (date) — Filing Date
- 2024-12-31 (date) — Fiscal Year End
FAQ
What were the total equity awards granted to PEO members in 2024?
The filing indicates data for 'EqtyAwrdsInSummryCompstnTblForAplblYrMember' and 'EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember' for PEO members for the year 2024, but specific dollar amounts are not provided in this excerpt.
Were there any adjustments made to equity awards for non-PEO NEO members in 2024?
Yes, the filing references 'EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember' for 'NonPeoNeoMember' for the period 2024, suggesting adjustments were made.
What is the company's Standard Industrial Classification (SIC) code?
The SIC code for Lisata Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
When did the company change its name from Caladrius Biosciences, Inc.?
Lisata Therapeutics, Inc. changed its name from Caladrius Biosciences, Inc. on August 8, 2017.
What is the company's principal executive office address?
The business address is 110 Allen Road, Second Floor, Basking Ridge, NJ 07920.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 25, 2025 regarding LISATA THERAPEUTICS, INC. (LSTA).